Magnus Lindskog

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Docent i experimentell onkologi. Kliniskt verksam som läkare inom onkologi.
I mitt arbete kombinerar jag patientverksamhet på en onkologisk
universitetsklinik (Akademiska sjukhuset) med patientnära cancerforskning,
doktorandhandledning och undervisning av läkarstudenter.
Medlem av styrgruppen för den Nationella Forskarskolan för Klinisk
Cancerforskning (NatiOn), Svenska Njurcancergruppen, och Svenska
Palliativregistrets Forskargrupp.

Forskningsbeskrivning

Fokus ligger på (1) anti-angiogena och anti-inflammatoriska substansers
användbarhet i behandlingen av svårt sjuka cancerpatienter, främst
njurcancer och lungcancer
(2) Symtomkontroll hos cancerpatienter i livets
slutskede.

Artiklar

Article: JAMA NETWORK OPEN. 2023;6(3):e234149
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial
Werlenius K; Kinhult S; Solheim TS; Magelssen H; Loefgren D; Mudaisi M; Hylin S; Bartek JJ; Strandeus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen O; Jakola AS
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(5-6):383-390
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
Rosenblad AK; Sundqvist P; Harmenberg U; Hellstrom M; Hofmann F; Kjellman A; Dahlin B-IK; Lindblad P; Lindskog M; Lundstam S; Ljungberg B
Article: BMC PALLIATIVE CARE. 2022;21(1):133
Acute healthcare utilization in end-of-life among Swedish brain tumor patients - a population based register study
Lindskog M; Schultz T; Strang P
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;40:38-45
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Lindskog M; Laurell A; Kjellman A; Melichar B; Rey PM; Zielinski H; Villacampa F; Bigot P; Zoltan B; Parikh O; Alba DV; Jellvert D; Flasko T; Gallardo E; Caparros MJR; Purkalne G; Suenaert P; Karlsson-Parra A; Ljungberg B
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;39:22-28
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study
Almdalal T; Sundqvist P; Harmenberg U; Hellstrom M; Lindskog M; Lindblad P; Lundstam S; Ljungberg B
Article: ACTA NEUROCHIRURGICA. 2021;163(2):333-342
Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery
Stenman M; Benmakhlouf H; Wersall P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: ACTA ONCOLOGICA. 2019;58(4):432-438
Cancer patients hospitalised in the last week of life risk insufficient care quality - a population-based study from the Swedish Register of Palliative Care
Elmstedt S; Mogensen H; Hallmans D-E; Tavelin B; Lundstrom S; Lindskog M
Article: ACTA ONCOLOGICA. 2019;58(3):306-312
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres
Stenman M; Staehler M; Szabados B; Sandstrom P; Laurell A; Lindskog M; Harmenberg U
Article: CANCER MANAGEMENT AND RESEARCH. 2019;11:1289-1297
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis
Redig J; Dalen J; Harmenberg U; Lindskog M; Ljungberg B; Lundstam S; Sandin R; Wahlgren T; Akerborg O; Jakobsson M
Article: RADIOTHERAPY AND ONCOLOGY. 2018;127(3):501-506
Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014
Stenman M; Sinclair G; Paavola P; Wersall P; Harmenberg U; Lindskog M
Article: F1000RESEARCH. 2018;7:1797
Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.
Jakola AS; Werlenius K; Mudaisi M; Hylin S; Kinhult S; Bartek J; Salvesen Ø; Carlsen SM; Strandéus M; Lindskog M; Löfgren D; Rydenhag B; Carstam L; Gulati S; Solheim O; Bartek J; Solheim T
Article: UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS. 2017;35(9):541.e15-541.e22
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Article: BMC MEDICAL ETHICS. 2016;17(1):30
Heed or disregard a cancer patient's critical blogging? An experimental study of two different framing strategies
Lynoe N; NattochDag S; Lindskog M; Juth N
Article: EUROPEAN JOURNAL OF CANCER. 2015;51(10):1331-1339
Old age as risk indicator for poor end-of-life care quality - A population-based study of cancer deaths from the Swedish Register of Palliative Care
Lindskog M; Tavelin B; Lundstrom S
Article: MEDICAL ONCOLOGY. 2014;31(3):841
Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma
Stenman M; Laurell A; Lindskog M
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):843-848
Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion
Al Hashmi S; Sadeghi B; Hassan Z; Abedi-Valugerdi M; Lindskog M; Hassan M
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(1):115-120
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;128(7):1703-1711
Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo
Gleissman H; Segerstrom L; Hamberg M; Ponthan F; Lindskog M; Johnsen JI; Kogner P
Article: LEUKEMIA AND LYMPHOMA. 2010;51(11):2092-2097
Fish oil delays lymphoma progression in the TLL mouse
Johansson A-S; Noren-Nystrom U; Larefalk A; Holmberg D; Lindskog M
Article: THE FASEB JOURNAL. 2010;24(3):906-915
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates
Gleissman H; Yang R; Martinod K; Lindskog M; Serhan CN; Johnsen JI; Kogner P
Article: JOURNAL OF NATURAL PRODUCTS. 2009;72(11):1969-1974
Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs
Felth J; Rickardson L; Rosen J; Wickstrom M; Fryknas M; Lindskog M; Bohlin L; Gullbo J
Article: LEUKEMIA AND LYMPHOMA. 2009;50(7):1198-1203
Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide
Johansson A-S; Pawelzik S-C; Larefalk A; Jakobsson P-J; Holmberg D; Lindskog M
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(5):1227-1234
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo
Paimberg E; Johnsen JI; Paulsson J; Gleissman H; Wickstrom M; Edgren M; Ostman A; Kogner P; Lindskog M
Article: MOLECULAR CANCER THERAPEUTICS. 2007;6(9):2409-2417
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Wickstrom M; Johnsen JI; Ponthan F; Segerstrom L; Sveinbjornsson B; Lindskog M; Lovborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;118(10):2584-2593
Neuroblastoma cell death in response to docosahexaenoic acid: Sensitization to chemotherapy and arsenic-induced oxidative stress
Lindskog M; Gleissman H; Ponthan F; Castro J; Kogner P; Johnsen JI
Article: CANCER RESEARCH. 2004;64(20):7210-7215
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2004;96(19):1457-1466
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma
Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
Article: ONCOLOGY REPORTS. 2003;10(5):1587-1592
Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts
Ponthan F; Lindskog M; Karnehed N; Castro J; Kogner P
Article: BRITISH JOURNAL OF CANCER. 2003;88(3):478-485
Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (¹H MRS)
Lindskog M; Kogner P; Ponthan F; Schweinhardt P; Sandstedt B; Heiden T; Helms G; Spenger C
Article: CLINICAL CHEMISTRY. 2003;49(1):104-112
Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastorna cells in blood and bone marrow
Träger C; Kogner P; Lindskog M; Ponthan F; Kullman A; Kågedal B
Visa fler

Alla övriga publikationer

Other: SURGICAL NEUROLOGY INTERNATIONAL. 2020;11:21
Adaptive radiosurgery based on two simultaneous dose prescriptions in the management of large renal cell carcinoma brain metastases in critical areas: Towards customization.
Sinclair G; Stenman M; Benmakhlouf H; Johnstone P; Wersäll P; Lindskog M; Hatiboglu MA; Harmenberg U
Review: CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE. 2014;8(4):378-382
Glycaemic control in end-of-life care: fundamental or futile?
Lindskog M; Karvestedt L; Furst CJ
Review: CANCER LETTERS. 2005;228(1-2):195-201
NSAIDs in neuroblastoma therapy
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Review: CANCER LETTERS. 2005;228(1-2):247-255
Proton magnetic resonance spectroscopy in neuroblastoma:: Current status, prospects and limitations
Lindskog M; Spenger C; Klason T; Jarvet J; Gräslund A; Johnsen JI; Ponthan F; Douglas L; Nordell B; Kogner P
Thesis / dissertation: 2004
Tumor lipid status and the responses to therapy in neuroblastoma : with emphasis on treatment monitoring by proton magnetic resonance spectroscopy
Lindskog, Magnus
Published conference paper: SPECTROSCOPY. 2004;18(2):123-132
Monitoring intracellular metabolites in neuroblastoma with 1H NMR spectroscopy: effects of growth factor withdrawal and modulation of lipid metabolism
Lindskog M; Jarvet J; Graslund A; Kogner P

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2022-2025

Examina och utbildning

Läkarexamen, Karolinska Institutet, 2006
MEDICINE DOKTORSEXAMEN, Institutionen för kvinnors och barns hälsa, Karolinska Institutet, 2004

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI